A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome

NCT00999518

Last updated date
Study Location
Alabama Orthopaedic Clinic
Mobile, Alabama, 36608, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Interstitial Cystitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with interstitial cystitis/ painful bladder syndrome for more than 6 months with moderate to severe pain and a micturition frequency greater than 7 per day.

- Patients who have been on stable oral medicines for interstitial cystitis/ painful bladder syndrome for at least 3 months. Other therapies might need to be stopped.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients on certain recent treatments for interstitial cystitis/ painful bladder
syndrome.


- Body mass index (BMI) of >39 kg/m2.


- History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal
antibody or IgG-fusion protein.


- Patients with peripheral neuropathy.


- Patients with Type I or type II diabetes mellitus who have an HbA1c > 8.0%.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Interstitial CystitisAn Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis
NCT00601484
  1. Peoria, Arizona
  2. Fresno, California
  3. Glendora, California
  4. San Diego, California
  5. Boulder, Colorado
  6. Hartford, Connecticut
  7. Hartford, Connecticut
  8. Middlebury, Connecticut
  9. New Britain, Connecticut
  10. New London, Connecticut
  11. Atlanta, Georgia
  12. Jeffersonville, Indiana
  13. Shreveport, Louisiana
  14. Owings Mills, Maryland
  15. Royal Oak, Michigan
  16. Troy, Michigan
  17. Utica, Michigan
  18. St. Louis, Missouri
  19. Omaha, Nebraska
  20. New Hyde Park, New York
  21. Rochester, New York
  22. Greensboro, North Carolina
  23. Cincinnati, Ohio
  24. Bethany, Oklahoma
  25. Pittsburgh, Pennsylvania
  26. Greer, South Carolina
  27. Houston, Texas
  28. Mountlake, Washington
  29. Spokane, Washington
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Interstitial CystitisA Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome
NCT00999518
  1. Mobile, Alabama
  2. Mobile, Alabama
  3. Glendale, Arizona
  4. Phoenix, Arizona
  5. Phoenix, Arizona
  6. Phoenix, Arizona
  7. Phoenix, Arizona
  8. Phoenix, Arizona
  9. Phoenix, Arizona
  10. Phoenix, Arizona
  11. Scottsdale, Arizona
  12. Tucson, Arizona
  13. Tucson, Arizona
  14. Beverly Hills, California
  15. Fresno, California
  16. Glendora, California
  17. Long Beach, California
  18. Los Angeles, California
  19. Murrieta, California
  20. Murrieta, California
  21. Signal Hill, California
  22. Boulder, Colorado
  23. Longmont, Colorado
  24. Longmont, Colorado
  25. Farmington, Connecticut
  26. New Britain, Connecticut
  27. New Britain, Connecticut
  28. Stamford, Connecticut
  29. Stamford, Connecticut
  30. Dover, Delaware
  31. Dover, Delaware
  32. Boynton Beach, Florida
  33. Jacksonville, Florida
  34. Lake Worth, Florida
  35. Naples, Florida
  36. New Port Richey, Florida
  37. New Port Richey, Florida
  38. New Port Richey, Florida
  39. Ocala, Florida
  40. Ocala, Florida
  41. Ocala, Florida
  42. Pinellas Park, Florida
  43. Saint Petersburg, Florida
  44. Trinity, Florida
  45. West Palm Beach, Florida
  46. Alpharetta, Georgia
  47. Alpharetta, Georgia
  48. Atlanta, Georgia
  49. Atlanta, Georgia
  50. Atlanta, Georgia
  51. Decatur, Georgia
  52. Evansville, Indiana
  53. Jeffersonville, Indiana
  54. Newburgh, Indiana
  55. Noblesville, Indiana
  56. Noblesville, Indiana
  57. West Des Moines, Iowa
  58. West Des Moines, Iowa
  59. Shreveport, Louisiana
  60. Annapolis, Maryland
  61. Annapolis, Maryland
  62. Brighton, Massachusetts
  63. Fall River, Massachusetts
  64. Grand Rapids, Michigan
  65. Kalamazoo, Michigan
  66. Kalamazoo, Michigan
  67. Kalamazoo, Michigan
  68. Royal Oak, Michigan
  69. Troy, Michigan
  70. Edina, Minnesota
  71. Edina, Minnesota
  72. Southaven, Mississippi
  73. Lincoln, Nebraska
  74. Lincoln, Nebraska
  75. Albany, New York
  76. Kingston, New York
  77. Kingston, New York
  78. New York, New York
  79. Poughkeepsie, New York
  80. Poughkeepsie, New York
  81. Rochester, New York
  82. Rochester, New York
  83. Salisbury, North Carolina
  84. Salisbury, North Carolina
  85. Winston-Salem, North Carolina
  86. Cincinnati, Ohio
  87. Cofumbus, Ohio
  88. Columbus, Ohio
  89. Westerville, Ohio
  90. Oklahoma City, Oklahoma
  91. Tulsa, Oklahoma
  92. Tulsa, Oklahoma
  93. Allentown, Pennsylvania
  94. Bala-Cynwyd, Pennsylvania
  95. Philadelphia, Pennsylvania
  96. Greer, South Carolina
  97. Greer, South Carolina
  98. Bristol, Tennessee
  99. Bristol, Tennessee
  100. Knoxville, Tennessee
  101. Knoxville, Tennessee
  102. Knoxville, Tennessee
  103. Memphis, Tennessee
  104. Memphis, Tennessee
  105. Memphis, Tennessee
  106. Nashville, Tennessee
  107. Nashville, Tennessee
  108. Nashville, Tennessee
  109. Nashville, Tennessee
  110. Nashville, Tennessee
  111. Houston, Texas
  112. Houston, Texas
  113. Houston, Texas
  114. Houston, Texas
  115. Murray, Utah
  116. Murray, Utah
  117. Salt Lake City, Utah
  118. Salt Lake City, Utah
  119. Salt Lake City, Utah
  120. Mountlake Terrace, Washington
  121. Mountlake Terrace, Washington
  122. Seattle, Washington
  123. Brussel,
  124. Edegem,
  125. Gent,
  126. Leuven,
  127. Abbotsford, British Columbia
  128. Barrie, Ontario
  129. Kingston, Ontario
  130. Kingston, Ontario
  131. Kitchener, Ontario
  132. Thunder Bay, Ontario
  133. Toronto, Ontario
  134. Sherbrooke, Quebec
  135. Kouvola,
  136. Shatin, NEW Territories
  137. Shatin,
  138. Fukuoka-shi, Fukuoka
  139. Nakagyo-ku, Kyoto-shi, Kyoto
  140. Arakawa-ku, Tokyo
  141. Bunkyo-ku, Tokyo
  142. Songpa-gu, Seoul
  143. Seoul,
  144. Seoul,
  145. Seoul,
  146. Bialystok,
  147. Warszawa,
  148. Warszawa,
  149. Warszawa,
  150. Warszawa,
  151. Bucuresti, Sector 4
  152. Bucuresti,
  153. Pantelimon,
  154. Moscow,
  155. Moscow,
  156. Saint-Petersburg,
  157. St. Petersburg,
  158. St. Petersburg,
  159. Martin,
  160. Martin,
  161. Presov,
  162. Majadahonda, Madrid
  163. Barcelona,
  164. Barcelona,
  165. Goteborg,
  166. Malmo,
  167. Malmo,
  168. Koahsiung Hsien,
  169. Taichung City,
  170. Taipei,
  171. Taipei,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Interstitial CystitisStudy Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis
NCT00275379
  1. Glendora, California
  2. Redding, California
  3. San Diego, California
  4. Aventura, Florida
  5. Kansas City, Kansas
  6. Jackson, Michigan
  7. Springfield, Oregon
  8. Philadelphia, Pennsylvania
  9. Philadelphia, Pennsylvania
  10. Philadelphia, Pennsylvania
  11. Houston, Texas
  12. Temple, Texas
  13. Mountlake Terrace, Washington
  14. Baden,
  15. Homburg/Saar,
  16. Munster,
Female
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome
Official Title  ICMJE A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS).
Brief Summary In a previous study in patients with interstitial cystitis/ painful bladder syndrome (IC/PBS), tanezumab has shown to be efficacious in relieving the pain associated with IC/PBS, as well as some effect on reducing urinary urgency. Only one dose was studied, and tanezumab was well tolerated. In this study, the hypothesis being tested is that tanezumab will show efficacy at several doses on reducing pain with sufficient tolerability. Tanezumab's safety will also be assessed at different dose levels
Detailed Description This study was terminated on 16 November 2010 following a US FDA partial clinical hold for the tanezumab interstitial cystitis clinical study announced on 19 July 2010 for potential safety issues, and following a pre-planned interim analysis.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Cystitis, Interstitial
Intervention  ICMJE
  • Biological: Tanezumab
    1 mg dose given subcutaneously twice at an 8-week interval.
  • Biological: Tanezumab
    2.5 mg dose given subcutaneously twice at an 8-week interval.
  • Biological: Tanezumab
    10 mg dose given subcutaneously twice at an 8-week interval.
  • Biological: Tanezumab
    20 mg dose given subcutaneously twice at an 8-week interval.
  • Other: Placebo
    Placebo dose given subcutaneously twice at an 8-week interval.
Study Arms  ICMJE
  • Experimental: Group 1
    Intervention: Biological: Tanezumab
  • Experimental: Group 2
    Intervention: Biological: Tanezumab
  • Experimental: Group 3
    Intervention: Biological: Tanezumab
  • Experimental: Group 4
    Intervention: Biological: Tanezumab
  • Placebo Comparator: Group 5
    Intervention: Other: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: May 23, 2019)
205
Original Estimated Enrollment  ICMJE
 (submitted: October 20, 2009)
360
Actual Study Completion Date  ICMJE January 21, 2011
Actual Primary Completion Date November 17, 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients with interstitial cystitis/ painful bladder syndrome for more than 6 months with moderate to severe pain and a micturition frequency greater than 7 per day.
  • Patients who have been on stable oral medicines for interstitial cystitis/ painful bladder syndrome for at least 3 months. Other therapies might need to be stopped.

Exclusion Criteria:

  • Patients on certain recent treatments for interstitial cystitis/ painful bladder syndrome.
  • Body mass index (BMI) of >39 kg/m2.
  • History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal antibody or IgG-fusion protein.
  • Patients with peripheral neuropathy.
  • Patients with Type I or type II diabetes mellitus who have an HbA1c > 8.0%.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium,   Canada,   Finland,   Hong Kong,   Japan,   Korea, Republic of,   Poland,   Romania,   Russian Federation,   Slovakia,   Spain,   Sweden,   Taiwan,   United States
Removed Location Countries Germany,   India,   South Africa
 
Administrative Information
NCT Number  ICMJE NCT00999518
Other Study ID Numbers  ICMJE A4091035
2009-014597-17 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date May 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP